Initiation, Dose Reduction, and Duration of Inhaled Corticosteroid Therapy - 18/08/11
Résumé |
Asthma is characterized by persistent airway inflammation, which is associated with airway hyperresponsiveness and variable airflow obstruction, which accounts for the majority of symptoms experienced by asthmatic patients. Allergen sensitization and inhalation causes airway inflammation, and is likely important in the initiation and persistence of asthma in more than 50% of patients, and while allergen avoidance (or avoidance of other initiating factors, such as occupational sensitizers) can help some patients, it is often difficult to achieve. For this reason, pharmacologic treatment to reduce airway inflammation is currently the cornerstone of therapy for most individuals who have asthma.
Le texte complet de cet article est disponible en PDF.Plan
| Paul M. O'Byrne is a consultant, is an advisory board member, and/or receives grants-in-aid from Altana Pharma, AstraZeneca, Biolipox, GlaxoSmithKline, IVAX, Pfizer, Roche, and Topigen. He does not own any stock options or shares in any pharmaceutical company. |
Vol 25 - N° 3
P. 511-521 - août 2005 Retour au numéro
Article précédent
- Glucocorticosteroids in Allergic Inflammation: Clinical Benefits in Allergic Rhinitis, Rhinosinusitis, and Otitis Media
- P. van Cauwenberge, H. Van Hoecke, L. Vandenbulcke, T. Van Zele, C. Bachert
- Benefit Versus Risk for Oral, Inhaled, and Nasal Glucocorticosteroids
- Kevin J. Mortimer, Anne E. Tattersfield
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?